Advanced search
Publication Cover
International Journal of General Medicine Volume 16, 2023 - Issue
Submit an article Journal homepage
229
Views
0
CrossRef citations to date
0
Altmetric
Infectious Diseases

Safety of Inactivated SARS-CoV-2 Vaccines Among Adults with Experience of Allergies to Food or Medicines

Yan Jin1 Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of China;2 Department of Respiratory and Critical Care Medicine, Municipal Hospital Affiliated to Taizhou University, Taizhou, People’s Republic of ChinaView further author information
,
Mengmeng Zheng1 Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of ChinaView further author information
,
Shiyi He1 Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of ChinaView further author information
,
Meiping Chen1 Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of ChinaView further author information
&
Chao Cao1 Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 3105-3113 | Received 21 May 2023, Accepted 14 Jul 2023, Published online: 21 Jul 2023

References

  • McNamara LA, Wiegand RE, Burke RM, et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. Lancet. 2022;399(10320):152–160. doi:10.1016/S0140-6736(21)02226-1
  • Nordstrom P, Ballin M, Nordstrom A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399(10327):814–823. doi:10.1016/S0140-6736(22)00089-7
  • Li M, Wang H, Tian L, et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. 2022;7(1):146. doi:10.1038/s41392-022-00996-y
  • Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, Phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(12):1645–1653. doi:10.1016/S1473-3099(21)00319-4
  • Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:10.1016/S1473-3099(20)30831-8
  • Palacios R, Patiño EG, de Oliveira Piorelli R, et al. Double-blind, randomized, placebo-controlled phase iii clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by Sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):853. doi:10.1186/s13063-020-04775-4
  • Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219–226. doi:10.1016/j.ijid.2021.08.013
  • Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, Phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222. doi:10.1016/S0140-6736(21)01429-X
  • Chen M, Li Y, Chen J, et al. An online survey of the attitude and willingness of Chinese adults to receive COVID-19 vaccination. Hum Vaccin Immunother. 2021;17(7):2279–2288. doi:10.1080/21645515.2020.1853449
  • Benjamanukul S, Traiyan S, Yorsaeng R, et al. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. J Med Virol. 2022;94(4):1442–1449. doi:10.1002/jmv.27458
  • Zhang M-X, Zhang T-T, Shi G-F, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20(7):891–898. doi:10.1080/14760584.2021.1925112
  • Choudhary OP, Mohammed TA, Singh I, Singh I. Intranasal COVID-19 vaccines: is it a boon or bane? Int J Surg. 2021;94:106119. doi:10.1016/j.ijsu.2021.106119
  • Choudhary OP, Choudhary OP. Vaccine efficacy against COVID-19: a foresight on the host-associated factors. J Formos Med Assoc. 2021;120(6):1405–1407. doi:10.1016/j.jfma.2020.11.021
  • Cao C, Qiu F, Lou C, et al. Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases. Respir Res. 2022;23(1):133. doi:10.1186/s12931-022-02054-1
  • Vander Leek TK, Chan ES, Connors L, et al. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. 2021;17(1):29. doi:10.1186/s13223-021-00529-2
  • Muraro A, Worm M, Alviani C, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy. 2022;77(2):357–377. doi:10.1111/all.15032

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.